A bright future for KRAS inhibitors

Dafna Bar-Sagi¹, Erik H Knelson^{2

3

4}, Lecia V Sequist^{5

6}

Affiliations

¹ Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA. dafna.bar-sagi@nyulangone.org.
² Dana Farber Cancer Institute, Boston, MA, USA.
³ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁴ Harvard Medical School, Boston, MA, USA.
⁵ Massachusetts General Hospital Cancer Center, Boston, MA, USA. lvsequist@partners.org.
⁶ Harvard Medical School, Boston, MA, USA. lvsequist@partners.org.

Dafna Bar-Sagi et al. Nat Cancer. 2020 Jan.

. 2020 Jan;1(1):25-27.

doi: 10.1038/s43018-019-0016-8.

Dafna Bar-Sagi¹, Erik H Knelson^{2

3

4}, Lecia V Sequist^{5

6}

¹ Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA. dafna.bar-sagi@nyulangone.org.
² Dana Farber Cancer Institute, Boston, MA, USA.
³ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
⁴ Harvard Medical School, Boston, MA, USA.
⁵ Massachusetts General Hospital Cancer Center, Boston, MA, USA. lvsequist@partners.org.
⁶ Harvard Medical School, Boston, MA, USA. lvsequist@partners.org.

No abstract available

References

1. Ostrem, J. M. & Shokat, K. M. Nat Rev. Drug Discov. 15, 771–785 (2016). - DOI
1. Canon, J. et al. Nature 575, 217–223 (2019). - DOI
1. Hallin, J. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-1167 (2019).
1. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013). - DOI
1. Castellano, E. & Downward, J. Genes Cancer 2, 261–274 (2011). - DOI